Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Targeting type 1 diabetes before and at the clinical onset of disease.

Bekris, L M ; Kavanagh, T J and Lernmark, Åke LU orcid (2006) In Endocrine, Metabolic & Immune Disorders - Drug Targets 6(1). p.103-124
Abstract
Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible... (More)
Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease. (Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
antioxidant, Oxidative Stress, Viral infections, Cadmium, CTLA-4, variable number tandem repeat (VNTR)
in
Endocrine, Metabolic & Immune Disorders - Drug Targets
volume
6
issue
1
pages
103 - 124
publisher
Bentham Science Publishers
external identifiers
  • scopus:33646065043
ISSN
2212-3873
DOI
10.2174/187153006776056576
language
English
LU publication?
yes
id
2e9b514d-b3d1-4cd1-92fe-6d37e6e2ad5c (old id 1136283)
date added to LUP
2016-04-01 16:14:37
date last changed
2021-10-03 05:31:33
@article{2e9b514d-b3d1-4cd1-92fe-6d37e6e2ad5c,
  abstract     = {Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease.},
  author       = {Bekris, L M and Kavanagh, T J and Lernmark, Åke},
  issn         = {2212-3873},
  language     = {eng},
  number       = {1},
  pages        = {103--124},
  publisher    = {Bentham Science Publishers},
  series       = {Endocrine, Metabolic & Immune Disorders - Drug Targets},
  title        = {Targeting type 1 diabetes before and at the clinical onset of disease.},
  url          = {http://dx.doi.org/10.2174/187153006776056576},
  doi          = {10.2174/187153006776056576},
  volume       = {6},
  year         = {2006},
}